Scroll Back to Top
Accessibility
Accessibility

KRAS Mutation Analysis (Extended) in Colorectal Cancer (CRC)

CPT 81275; 81276; 88381

Test Details

Cancer Type

Colorectal cancer (CRC)

Technology Used

Molecular

Turnaround Time

5 - 7 days

View Requisition Forms

Use

KRAS is a guanosine triphosphate (GTP) binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival, and differentiation. Mutations in the KRAS oncogene are frequently found in human cancers. They are common in pancreatic, colorectal, lung, gallbladder, bile duct, and thyroid cancer. This assay will detect KRAS mutations in exons 2, 3, and 4, allowing the determination of drug response.

Special Instructions

Provide a copy of the pathology report; the KRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363.

Limitations

This assay is able to detect 5% mutation in a background of wild-type DNA.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Methodology

SNaPshot Multiplex PCR (primer extension-based method)

Specimen Requirements

Information on collection, storage, and volume

Specimen

Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides.

Volume

Formalin-fixed, paraffin-embedded tissue block or four unstained slides and one matching H&E-stained slide at 5 µM.

Minimum Volume

Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4 mm² and ≥50% tumor content are preferred.

Container

FFPE tissue blocks or slides.

Storage Instructions

Maintain blocks and slides at room temperature.

Causes for Rejection

Tumor block containing no tumor tissue; broken or stained slides

Request Supplies